Travere Therapeutics Inc
NASDAQ:TVTX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
5.26
19.85
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Travere Therapeutics Inc
Travere Therapeutics Inc
Total Receivables
Travere Therapeutics Inc
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Travere Therapeutics Inc
NASDAQ:TVTX
|
Total Receivables
$25.2m
|
CAGR 3-Years
22%
|
CAGR 5-Years
8%
|
CAGR 10-Years
18%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Receivables
$11.5B
|
CAGR 3-Years
7%
|
CAGR 5-Years
16%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Receivables
$4.6B
|
CAGR 3-Years
0%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Receivables
$7.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
15%
|
CAGR 10-Years
12%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Receivables
$1.8B
|
CAGR 3-Years
17%
|
CAGR 5-Years
32%
|
CAGR 10-Years
31%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Receivables
$6.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
18%
|
CAGR 10-Years
21%
|
|
Travere Therapeutics Inc
Glance View
Travere Therapeutics Inc., a biopharmaceutical trailblazer, has carved a niche in the healthcare landscape by focusing on the often-overlooked realm of rare diseases. With a mission to improve the lives of patients grappling with conditions that lack sufficient treatment options, Travere leverages its deep expertise in research, development, and commercialization of therapies. Beyond generic pharmaceuticals, the company's extensive pipeline is filled with innovative treatments, targeting conditions from chronic kidney diseases to rare liver disorders. This strategic emphasis on rare diseases not only exemplifies Travere's commitment to social responsibility but also positions it uniquely within the competitive pharmaceutical sector, where the rarity of these conditions often results in limited competition. The financial lifeline of Travere Therapeutics comes from its ability to navigate the intricate process of bringing drugs from conception to market. Revenue streams are primarily driven by the sales of FDA-approved products, alongside milestone and royalty payments tied to strategic collaborations. The company’s shrewd strategy involves acquiring or licensing promising compounds and utilizing its robust in-house capabilities to carry these assets through clinical trials. This intertwined web of internal development and strategic partnerships creates a sustainable business model. It ensures that as current treatments mature and stabilize their market presence, new pipeline products are continually groomed, keeping revenue streams dynamic while reinforcing their commitment to addressing unmet medical needs.
See Also
What is Travere Therapeutics Inc's Total Receivables?
Total Receivables
25.2m
USD
Based on the financial report for Sep 30, 2024, Travere Therapeutics Inc's Total Receivables amounts to 25.2m USD.
What is Travere Therapeutics Inc's Total Receivables growth rate?
Total Receivables CAGR 10Y
18%
Over the last year, the Total Receivables growth was 72%. The average annual Total Receivables growth rates for Travere Therapeutics Inc have been 22% over the past three years , 8% over the past five years , and 18% over the past ten years .
You don't have any saved screeners yet
